Physician profile
Vishal Devarkonda
NPI 1932620663
$2,577.33
in general payments reported to CMS, 2019-2025
38 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.75 · 2022: $56.67 · 2023: $69.93 · 2024: $942 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052 · Education: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.98 |
| Education | $446.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $316.09 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $278.48 | 2024-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $200.68 | 2023-2025 | Calquence, Lynparza, Fasenra |
| Novartis Pharmaceuticals Corporation | $179.93 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $142.74 | 2021-2024 | Xarelto |
| Csl Behring | $125.00 | 2024 | Hemgenix |
| Abbvie INC. | $122.24 | 2024-2025 | |
| Pfizer INC. | $101.62 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $93.95 | 2024 | Soliris |
| Glaxosmithkline, LLC. | $92.66 | 2025 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $80.45 | 2025 | Reblozyl, Breyanzi |
| Genentech, INC. | $77.76 | 2024 | Columvi |
| Rigel Pharmaceuticals, INC. | $63.78 | 2024 | Tavalisse, Rezlidhia |
| Merck Sharp & Dohme LLC | $62.50 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Beone Medicines USA, INC. | $60.12 | 2025 | Brukinsa |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Devarkonda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.